Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

- PMLiVE

Boehringer Ingelheim calls for “strong and united” Europe

Simone Menne highlights the EU's achievements, and her firm's contribution

- PMLiVE

Pfizer keeps nose ahead of rivals with new Ibrance approval

FDA licenses new indication for the breast cancer treatment

Roche Basel Switzerland

Roche sets disruptive price for new MS drug Ocrevus in US

Firm will significantly under cut rivals like Merck's Rebif

- PMLiVE

UK pharma strikes optimistic note as Brexit process begins

Says life science industry is accustomed to ‘uncertainty’ and can thrive in a post-EU Britain

- PMLiVE

Brexit begins as UK PM signs letter triggering Article 50

Theresa May sets wheels in motion as Britain awaits EU response

- PMLiVE

Amgen wins European approval for Humira biosimilar Amgevita

European Commission approves the first version of AbbVie's blockbuster

- PMLiVE

A new decade of disruption: meeting the biosimilar challgenge

Ten years after biosimilars first rocked their boat, how will biologics stay competitive?

- PMLiVE

Mylan deal with Roche clears path to biosimilar Herceptin launch

Covers global markets with the exception of Japan, Brazil and Mexico

Novartis day

FDA approval for Kisqali sets up showdown with Ibrance

Novartis breast cancer therapy drug has been predicted to reach blockbuster status

- PMLiVE

Merck confirms sale of biosimilar division

German pharma group is in 'advanced discussions' with potential buyers

Deal Watch February 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links